Mark Ragosa - 02 Nov 2026 Form 4 Insider Report for Kiniksa Pharmaceuticals International, plc (KNSA)

Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
03 Nov 2026, 18:32:40 UTC
Prior SEC filing
03 Sep 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Douglas Barry, Attorney-in-Fact
Filing notes and source

Key filing fact

Mark Ragosa filed Form 4 for Kiniksa Pharmaceuticals International, plc (KNSA) on 03 Nov 2026.

Key facts

  • This page summarizes Mark Ragosa's Form 4 filing for Kiniksa Pharmaceuticals International, plc (KNSA).
  • 12 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 03 Nov 2026, 18:32.

Change

  • Previous filing in this sequence was filed on 03 Sep 2026.
  • Current net transaction value: -$3,389,975.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001835458 Primary reporting owner

Ragosa Mark

Relationship
CHIEF FINANCIAL OFFICER
Address
C/O KINIKSA PHARMACEUTICALS INT'L, 105 PICCADILLY, SECOND FLOOR, LONDON, UNITED KINGDOM
Signature
/s/ Douglas Barry, Attorney-in-Fact
Signature date
03 Nov 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+9,636
Change %
+46%
Price
$10.76*
Shares after
30,490
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+5,388
Change %
+18%
Price
$11.10*
Shares after
35,878
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+12,123
Change %
+34%
Price
$11.97*
Shares after
48,001
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Options Exercise

Transaction value
Shares
+9,636
Change %
+20%
Price
$17.76*
Shares after
57,637
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$1,282,068
Shares
-14,027
Change %
-24%
Price
$91.40
Shares after
43,610
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F2
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$966,499
Shares
-10,502
Change %
-24%
Price
$92.03
Shares after
33,108
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F3
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$1,120,726
Shares
-12,034
Change %
-36%
Price
$93.13
Shares after
21,074
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F4
KNSA transaction

Class A Ordinary Share

Sale

Transaction value
-$20,682
Shares
-220
Change %
-1%
Price
$94.01
Shares after
20,854
Date
02 Nov 2026
Ownership
Direct
Footnotes
F1, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
Shares
-9,636
Change %
-69%
Price
$0.000000*
Shares after
4,380
Date
02 Nov 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
9,636
Exercise price
$10.76
Footnotes
F1, F6
KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
Shares
-5,388
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
5,388
Exercise price
$11.10
Footnotes
F7
KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
Shares
-12,123
Change %
-100%
Price
$0.000000*
Shares after
0
Date
02 Nov 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
12,123
Exercise price
$11.97
Footnotes
F1, F8
KNSA transaction Derivative

Share Option

Options Exercise

Transaction value
Shares
-9,636
Change %
-52%
Price
$0.000000*
Shares after
8,760
Date
02 Nov 2026
Ownership
Direct
Underlying class
Class A Ordinary Share
Underlying amount
9,636
Exercise price
$17.76
Footnotes
F1, F9
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 9 footnotes

Footnote F1

This transaction was effected pursuant to a 10b5-1 plan executed by the reporting person on July 29, 2026.

Footnote F2

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $90.695 and $91.675. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F3

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $91.695 and $92.60. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F4

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $92.735 and $93.725. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F5

This transaction was executed in multiple trades through a broker-dealer at prices ranging between $93.93 and $94.025. The price reported in this column reflects a weighted average sales price. Upon request, the reporting person will provide to the SEC staff full information regarding the number of Shares sold at each price.

Footnote F6

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 1, 2023.

Footnote F7

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is April 7, 2022.

Footnote F8

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2022.

Footnote F9

The option vests and becomes exercisable as to 25% of the total grant on the first anniversary of the vesting commencement date and vests in 36 equal monthly installments thereafter. The vesting commencement date is September 1, 2023.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .